Abstract :

Moyamoya disease is a rare and progressive cerebrovascular disorder marked by the occlusion or blockage of the distal internal carotid arteries and their main branches. In response, the brain develops a network of fragile collateral vessels, which appear as a “puff of smoke” on angiographic imaging—a characteristic feature that inspired the disease’s name. The condition primarily affects children and young adults, often presenting with transient ischemic attacks, strokes, seizures, or cerebral haemorrhage. Although the underlying mechanisms are not fully understood, genetic factors, particularly mutations in the RNF213 gene, have been closely associated with disease susceptibility, The major susceptibility gene for moyamoya disease in people investigation into the mechanisms of disease and potential treatment targets. The Arg4810Lys variant of the gene is most strongly associated with moyamoya disease, but the penetrance is lower than 1%, suggesting a synergistic relationship with additional environmental and genetic risk factors. A 11-year-old female patient presented with the complaints of sudden onset of left upper limb and lower limb transient weakness associated with bowel incontinence patient has  a past medical history of seizures since 10 months with multiple seizure episodes Diagnostic evaluation typically involves magnetic resonance imaging, magnetic resonance angiography, and digital subtraction angiography, the latter of which remains the gold standard. Treatment strategies are primarily surgical, with revascularization procedures—either direct, indirect, or combined approaches—aimed at improving cerebral blood flow and reducing the risk of ischemic events . Based on laboratory investigations and radiological reports case was diagnosed as MOYAMOYA DISEASE preoperative and anaesthesia clearance patient was taken up for STA-MCA bypass (Superficial Temporal Artery to Middle Cerebral Artery Bypass) associated  treatment with perivascular sympathectomy and superior cervical ganglionectomy may be useful but more investigation needs to be carried out into the pathogenesis of the disease before more definitive therapy is realized.

This review outlines the latest developments in the understanding, diagnosis, and management of Moyamoya disease, with attention to its genetic background and surgical outcomes.

---

Keywords :

Children, Moyamoya disease, Revascularization, stroke, Surgery.

---

References :

1. Kuroda, S., & Houkin, K. (2008). Moyamoya disease: Current concepts and future perspectives. The Lancet Neurology, 7(11), 1056–1066. https://doi.org/10.1016/S1474-4422(08)70240-0
2. Liu, W., Morito, D., Takashima, S., Mineharu, Y., Kobayashi, H., Hitomi, T., … & Koizumi, A. (2011). Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PLoS ONE, 6(7), e22542. https://doi.org/10.1371/journal.pone.0022542
3. Scott, R. M., & Smith, E. R. (2009). Moyamoya disease and moyamoya syndrome. New England Journal of Medicine, 360(12), 1226–1237. https://doi.org/10.1056/NEJMra0804622
4. Takanashi, J. (2011). Moyamoya disease in children. Brain and Development, 33(3), 229–236. https://doi.org/10.1016/j.braindev.2010.04.007
5. Guzman R, Lee M, Achrol A, et al. (2009). Clinical outcome after 450 revascularization procedures for moyamoya disease. Journal of Neurosurgery, 111(5), 927–935.
6. Funaki, T., et al. (2018). Hemorrhagic risk and prevention of rebleeding in moyamoya disease. Journal of Stroke, 20(2), 173–181. https://doi.org/10.5853/jos.2017.02759
7. Amlie-Lefond, C., et al. (2009). Risk factors for arterial ischemic stroke in children: A case-control study. The Lancet Neurology, 8(9), 893–899. https://doi.org/10.1016/S1474-4422(09)70222-0
8. Sato, M., et al. (2012). Moyamoya disease associated with antiphospholipid antibodies: A case report. Journal of Stroke and Cerebrovascular Diseases, 21(8), e19–e21. https://doi.org/10.1016/j.jstrokecerebrovasdis.2011.08.003
9. Bang, O. Y., et al. (2016). RNF213 polymorphism in patients with non-moyamoya intracranial atherosclerosis. Journal of Stroke, 18(2), 206–211. https://doi.org/10.5853/jos.2015.01186
10. Kraemer, M., et al. (2004). Moyamoya disease in Europeans. Stroke, 35(6), 1384–1387. https://doi.org/10.1161/01.STR.0000126044.60475.1b
11. Uchino, K., et al. (2005). Moyamoya disease in the United States. Stroke, 36(5), 947–951. https://doi.org/10.1161/01.STR.0000163084.30576.8b
12. Mesiwala, A. H., et al. (2008). Long-term outcome of superficial temporal artery-middle cerebral artery bypass for patients with Moyamoya disease. Journal of Neurosurgery, 109(6), 1024–1031. https://doi.org/10.3171/JNS/2008/109/12/1024
13. Yoshida, Y., et al. (2014). Cerebral hyperperfusion syndrome after bypass surgery in patients with Moyamoya disease. Neurosurgical Review, 37(2), 369–380. https://doi.org/10.1007/s10143-014-0531-9
14. Hirano, Y., et al. (2012). Increased levels of circulating endothelial progenitor cells and angiogenic factors in patients with Moyamoya disease. Clinical Neurology and Neurosurgery, 114(4), 355–358. https://doi.org/10.1016/j.clineuro.2011.10.004
15. Ikeda, A., et al. (2019). Inflammatory and immune markers in Moyamoya disease. Current Neurology and Neuroscience Reports, 19(8), 51. https://doi.org/10.1007/s11910-019-0971-3